Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data

Breast cancer is the most common type of cancer among women worldwide and in Japan. The majority of breast cancers are hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2‒), and endocrine therapy is an effective therapy for this type of breast cancer. However, rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Kosaka, Nobuyoshi, Iwata, Hiroji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580935/
https://www.ncbi.nlm.nih.gov/pubmed/34698970
http://dx.doi.org/10.1007/s10147-021-02013-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580935/
https://www.ncbi.nlm.nih.gov/pubmed/34698970
http://dx.doi.org/10.1007/s10147-021-02013-8

Ejemplares similares